|
Product complaint # (b)(4).To date the device has not been returned.If the device or further details are received at a later date a supplemental medwatch will be sent.Attempts are being made to obtain the following information.To date no response has been provided.If further details are received at a later date a supplemental medwatch will be sent.1.What were the diagnosis and indication for the index surgical procedure? 2.Please provide any relevant patient history: patient pre-existing medical conditions (i.E.Allergies, history of reactions), all concomitant medications, past medical history, any treatment required for events, dose, frequency, and therapy dates.3.Was there any intraoperative concurrent use of other products? 4.What was the intended use of the surgicel? was it used to address active bleeding or used prophylactically? 5.Where was the surgicel used (on what tissue)? 6.How much surgicel was used during the procedure? 7.Was the surgicel product left in place? was the excess removed? 8.Was the suture used an ethicon suture? if yes, what was the product code of the suture and was there any alleged deficiency related to the suture? 9.What were current symptoms following the index surgical procedure? what was the onset date? 10.Were cultures performed? if yes, results? 11.What is physician¿s opinion as to the cause of this event? 12.Was there an alleged deficiency of the surgicel that contributed to the patient¿s post-operative event? 13.What is the patient¿s current status? 14.What is the users experience w/ surgicel powder and other hemostatic agents? this report is being submitted pursuant to the provisions of 21 cfr part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|
|
It was reported that a patient underwent a hysterectomy procedure on (b)(6) 2025 and absorbable hemostat was used.After 15 days of the procedure, endometriosis and hysterectomy, the doctor reported there was a possible reaction to the absorbable hemostat.The patient presented pain and serous vaginal discharge on the third postoperative day.Vaginal imaging and touch tests were performed for analysis of endometrial suture.Seen serous drainage and performed antibiotic wash and started for 7 days (ciprofloxacin and metronidazole).Patient in follow-up by the team and finds themself well.Additional information was requested.
|
|
Product complaint # (b)(4).A manufacturing record evaluation was performed for the finished device batch and no non-conformances were identified.This report is being submitted pursuant to the provisions of 21 cfr part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|